<SEC-DOCUMENT>0001628280-25-005686.txt : 20250214
<SEC-HEADER>0001628280-25-005686.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214160321
ACCESSION NUMBER:		0001628280-25-005686
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ginkgo Bioworks Holdings, Inc.
		CENTRAL INDEX KEY:			0001830214
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				872652913
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92710
		FILM NUMBER:		25628143

	BUSINESS ADDRESS:	
		STREET 1:		27 DRYDOCK AVENUE
		STREET 2:		8TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(877) 442-5362

	MAIL ADDRESS:	
		STREET 1:		27 DRYDOCK AVENUE
		STREET 2:		8TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Soaring Eagle Acquisition Corp.
		DATE OF NAME CHANGE:	20210210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spinning Eagle Acquisition Corp.
		DATE OF NAME CHANGE:	20201027

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shetty Reshma P.
		CENTRAL INDEX KEY:			0001873523
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		C/O SOARING EAGLE ACQUISITION CORP.
		STREET 2:		955 FIFTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10075
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001873523</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
      <dateOfEvent>02/14/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001830214</issuerCIK>
        <issuerCUSIP>37611X209</issuerCUSIP>
        <issuerName>Ginkgo Bioworks Holdings, Inc.</issuerName>
        <address>
          <com:street1>27 Drydock Avenue</com:street1>
          <com:street2>8th Floor</com:street2>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02210</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ginkgo Bioworks Holdings, Inc.</personName>
          <personPhoneNum>8774225362</personPhoneNum>
          <personAddress>
            <com:street1>27 Drydock Avenue</com:street1>
            <com:street2>8th Floor</com:street2>
            <com:city>Boston</com:city>
            <com:stateOrCountry>MA</com:stateOrCountry>
            <com:zipCode>02210</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001873523</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Reshma P. Shetty</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4716084.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4716084.00</sharedDispositivePower>
        <aggregateAmountOwned>4716084.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.5</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Rows 8, 10 and 11 consist of (i) 618,726 shares of Class A Common Stock of the Issuer and (ii) 4,097,358 shares of Class B Common Stock of the Issuer. Each share of Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder.

Row 13 is based on (i) 45,575,423 shares of Class A Common Stock outstanding as of December 31, 2024, based on information provided by the Issuer to Reporting Persons, (ii) 4,097,358 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001882756</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Barry Canton</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4716084.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4716084.00</sharedDispositivePower>
        <aggregateAmountOwned>4716084.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>9.5</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Rows 8, 10 and 11 consist of (i) 618,726 shares of Class A Common Stock of the Issuer and (ii) 4,097,358 shares of Class B Common Stock of the Issuer. Each share of Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder.

Row 13 is based on (i) 45,575,423 shares of Class A Common Stock outstanding as of December 31, 2024, based on information provided by the Issuer to Reporting Persons, (ii) 4,097,358 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock.

This Amendment No. 4 (the "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons on September 27, 2021 and amended on October 1, 2022, January 24, 2023 and February 14, 2024 (the "Original Schedule 13D" and, as amended and supplemented by this Amendment, the "Schedule 13D") with respect to securities of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

This Amendment updates the Original Schedule 13D to reflect a reverse stock split of the Issuer's Class A Common Stock, Class B Common Stock and Class C Common Stock at a ratio of one-for-forty (1:40), effected by the Issuer in August 2024. This Amendment also reflects an increase in the Issuer's number of shares of Class A Common Stock outstanding. The foregoing updates result in a decrease in the percentage of Class A Common Stock beneficially owned by the Reporting Persons.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Class A Common Stock</securityTitle>
        <issuerName>Ginkgo Bioworks Holdings, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>27 Drydock Avenue</com:street1>
          <com:street2>8th Floor</com:street2>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02210</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item5>
        <percentageOfClassSecurities>This Amendment amends and restates Item 5 of the Original Schedule 13D in its entirety:
The information included in Item 4 is incorporated herein by reference.

The following sets forth, as of the date of this Amendment, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof:

Reshma Shetty: Amount beneficially owned: 4,716,084; Percent of class: 9.5%; Sole power to vote or to direct the vote: 0; Shared power to vote or to direct the vote: 4,716,084; Sole power to dispose or to direct the disposition: 0; Shared power to dispose or to direct the disposition: 4,716,084

Barry Canton: Amount beneficially owned: 4,716,084; Percent of class: 9.5%; Sole power to vote or to direct the vote: 0; Shared power to vote or to direct the vote: 4,716,084; Sole power to dispose or to direct the disposition: 0; Shared power to dispose or to direct the disposition: 4,716,084</percentageOfClassSecurities>
        <numberOfShares>The share amounts reflected in (a) above consist of the following: (i) 309,363 shares of Class A Common Stock and 58,005 shares of Class B Common Stock held of record by Ms. Shetty; (ii) 309,363 shares of Class A Common Stock and 58,005 shares of Class B Common Stock held of record by Mr. Canton; (iii) 1,754,744 shares of Class B Common Stock held of record by the Reshma Padmini Shetty Living Trust; (iv) 57,693 shares of Class B Common Stock held of record by Ms. Shetty's grantor retained annuity trust; (v) 1,749,744 shares of Class B Common Stock held of record by the Bartholomew Canton Living Trust; (vi) 57,693 shares of Class B Common Stock held of record by Mr. Canton's grantor retained annuity trust; (vii) 32,294 shares of Class B Common Stock held of record by The Asha S. Canton Irrevocable Trust and (viii) 32,294 shares of Class B Common Stock held of record by The Adhira S. Canton Irrevocable Trust. The Reporting Persons are married and may be deemed to share beneficial ownership over the shares held of record by each other and each of the foregoing trusts. Each share of Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder.

The percentages in (a) above are based on (i) 45,575,423 shares of Class A Common Stock outstanding as of December 31, 2024, based on information provided by the Issuer to Reporting Persons, (ii) 4,097,358 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock.</numberOfShares>
        <transactionDesc>Ms. Shetty has not effected any transactions in the Class A Common Stock during the past sixty days.
Mr. Canton has not effected any transactions in the Class A Common Stock during the past sixty days.</transactionDesc>
        <listOfShareholders>None.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Reshma P. Shetty</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Reshma P. Shetty</signature>
          <title>Reshma P. Shetty</title>
          <date>02/14/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Barry Canton</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Barry Canton</signature>
          <title>Barry Canton</title>
          <date>02/14/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
